EU project promotes access to ATMPs and their use in clinical practice

News /

The JOIN4ATMP project was launched in January. The project aims to help accelerate the development and broad availability of novel therapies in Europe. The Fraunhofer Institute for Cell Therapy and Immunology IZI is one of the 14 project partners from 9 countries.

As the standardized, conventional regulatory requirements for the approval of drugs cannot be directly transferred to complex gene and cell therapies, JOIN4ATMP will identify hurdles in the application and development of advanced therapy medicinal products (ATMPs) and develop possible standardized solutions to overcome these hurdles. The European University Hospital Alliance, the T2EVOLVE consortium and the RESTORE initiative are involved in the project, which is led by Charité - Universitätsmedizin Berlin. They are supported by industry partners and patient representatives, as well as other partners from the fields of ATMP development, production, application and regulation.

As a network partner in JOIN4ATMP, Fraunhofer IZI supports the European University Hospital Alliance in the development of ATMPs.

The project "Map, join and drive European activities for advanced therapy medicinal product development and implementation for the benefit of patients and society (JOIN4ATMP)" will run for three years and is funded by the European Union within the framework of Horizon Europe with almost 3 million euros.

You can find more information about the project here: